TNIK Therapeutics
Small Molecule Inhibitors of TNIK
Company Overview
Snapshot
Founded in May 2018, TNIK Therapeutics operates with 1–10 employees. The company has secured funding across one round from FuturX. In January 2019, the company received its seed funding.
Business overview
TNIK Therapeutics is a Health Tech & Life Sciences company focused on developing small molecule inhibitors for TNIK, a key transcription regulator in the Wnt pathway. The company's core technology targets cancer stem cell diseases, specifically metastatic colon cancer, by regulating the beta-catenin-TCF4 transcription complex. Operating within the Pharmaceuticals sector, TNIK Therapeutics aims to provide solutions for drug discovery and development, serving the life sciences and pharmaceutical industries.
Strategic signal
In February 2019, Severance Hospital transferred a colorectal cancer treatment candidate to TNIK Therapeutics. This indicates a strategic move to advance its pipeline and validates the company's focus on developing therapies for cancer stem cell diseases, signaling potential for future clinical development and market entry.
Company Intelligence Q&A
- What is TNIK Therapeutics' primary focus?
- TNIK Therapeutics focuses on developing small molecule inhibitors of TNIK to target cancer stem cell diseases, particularly metastatic colon cancer.
- When was TNIK Therapeutics founded?
- TNIK Therapeutics was founded in May 2018.
- What was a significant development for TNIK Therapeutics in early 2019?
- In February 2019, Severance Hospital transferred a colorectal cancer treatment candidate to TNIK Therapeutics, enhancing its development pipeline.
- What is the strategic importance of targeting TNIK?
- Targeting TNIK regulates the beta-catenin-TCF4 transcription complex, which is crucial for stemness and proliferation in colorectal carcinogenesis, offering a specific approach with reduced off-target effects.